Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea FDA rejected Friday local press reports that the Korean government - jittery over the rising number of local people infected with A/H1N1- will soon exercise the option of "compulsory licensing" to produce generic versions of Roche's Tamiflu (oseltamivir)

You may also be interested in...



Korea’s Celltrion Advances Its First Novel Therapy, Universal Influenza Treatment

Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.

South Korea Discusses Opening State-owned Pharma For Stable Drug Supply

The president of the National Health Insurance Service told lawmakers his agency is assessing the feasibility of a state-owned pharma, which the domestic industry group said could put a pinch on reimbursement negotiations.

GSK To Supply Korea With 3 Million Doses of A/H1N1 Flu Vaccine By Year End

SEOUL - As part of its bid to better tackle spreading A/H1N1 flu infections, South Korea's Ministry for Health, Welfare and Family Affairs has asked GlaxoSmithKline to supply three million doses of its A/H1N1 flu vaccine within the year, rather than next year as originally planned

Related Content

UsernamePublicRestriction

Register

SC072545

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel